A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy.

  • Wei, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date6/10/20 → 31/12/25

Keywords

  • Malignant Haematology
  • Acute Myeloid Leukaemia (AML)
  • Clinical trial